Impact of CYP2D6, CYP3A5, CYP2C9 and CYP2C19 polymorphisms on tamoxifen pharmacokinetics in Asian breast cancer patients
about
Applications of CYP450 testing in the clinical settingAnalysis of Genetic Variation in CYP450 Genes for Clinical ImplementationThe active tamoxifen metabolite endoxifen (4OHNDtam) strongly down-regulates cytokeratin 6 (CK6) in MCF-7 breast cancer cellsEffects of CYP2D6 and CYP3A5 polymorphisms on tamoxifen and its metabolites in Thai breast cancer patients.Prognostic and predictive biomarkers: tools in personalized oncology.Concomitant use of tamoxifen and endoxifen in postmenopausal early breast cancer: prediction of plasma levels by physiologically-based pharmacokinetic modeling.Far beyond the usual biomarkers in breast cancer: a review.Genetic factors affecting drug disposition in Asian cancer patients.Tamoxifen metabolism predicts drug concentrations and outcome in premenopausal patients with early breast cancer.The risk of recurrence in breast cancer patients treated with tamoxifen: polymorphisms of CYP2D6 and ABCB1.Effects of Pharmacogenetics on the Pharmacokinetics and Pharmacodynamics of Tamoxifen.CYP2D6 polymorphisms influence the efficacy of adjuvant tamoxifen in Thai breast cancer patientsFunctional polymorphisms in xenobiotic metabolizing enzymes and their impact on the therapy of breast cancer.ABCB1 and ABCC2 and the risk of distant metastasis in Thai breast cancer patients treated with tamoxifen.Influence of CYP2D6 polymorphisms on serum levels of tamoxifen metabolites in Spanish women with breast cancerAssociation of CYP2C19*2 and associated haplotypes with lower norendoxifen concentrations in tamoxifen-treated Asian breast cancer patients.Association of CYP2D6 and CYP2C19 polymorphisms and disease-free survival of Thai post-menopausal breast cancer patients who received adjuvant tamoxifenCYP2C19 2 predicts substantial tamoxifen benefit in postmenopausal breast cancer patients randomized between adjuvant tamoxifen and no systemic treatment.The Effect of Patient and Contextual Characteristics on Racial/Ethnic Disparity in Breast Cancer Mortality.Association of CYP3A4/5, ABCB1 and ABCC2 polymorphisms and clinical outcomes of Thai breast cancer patients treated with tamoxifen.Prevalence of CYP2D6*2, CYP2D6*4, CYP2D6*10, and CYP3A5*3 in Thai breast cancer patients undergoing tamoxifen treatment.Cytochrome P450 pharmacogenetics in African populations.Impact of metabolizing enzymes on drug response of endocrine therapy in breast cancer.Important and critical scientific aspects in pharmacogenomics analysis: lessons from controversial results of tamoxifen and CYP2D6 studies.Priority pharmacogenetics for the African continent: focus on CYP450.CYP2C19*2 and CYP2C19*17 variants and effect of tamoxifen on breast cancer recurrence: Analysis of the International Tamoxifen Pharmacogenomics Consortium dataset.Personalized in vitro cancer models to predict therapeutic response: Challenges and a framework for improvementCytochrome P-450 2D6 (CYP2D6) Genotype and Breast Cancer Recurrence in Tamoxifen-Treated Patients: Evaluating the Importance of Loss of Heterozygosity.Multigene and Drug Interaction Approach for Tamoxifen Metabolite Patterns Reveals Possible Involvement of CYP2C9, CYP2C19, and ABCB1.Pharmacogenetics of UGT1A4, UGT2B7 and UGT2B15 and Their Influence on Tamoxifen Disposition in Asian Breast Cancer Patients.Cytochrome P450 2D6 genotype affects the pharmacokinetics of controlled-release paroxetine in healthy Chinese subjects: comparison of traditional phenotype and activity score systems.Improved Prediction of Endoxifen Metabolism by CYP2D6 Genotype in Breast Cancer Patients Treated with Tamoxifen.Comparative study of polymorphism frequencies of the CYP2D6, CYP3A5, CYP2C8 and IL-10 genes in Mexican and Spanish women with breast cancer.CYP3A5*3 polymorphism and cancer risk: a meta-analysis and meta-regression.Editors' pick 2011.Variations in plasma concentrations of tamoxifen metabolites and the effects of genetic polymorphisms on tamoxifen metabolism in Korean patients with breast cancer.Pharmacogenomics Guided-Personalization of Warfarin and Tamoxifen.Cytochrome P450 Genetic Variation Associated with Tamoxifen Biotransformation in American Indian and Alaska Native People.Distribution of ABCB1, CYP3A5, CYP2C19, and P2RY12 gene polymorphisms in a Mexican Mestizos population.Cytochrome P450 2D6*10 genotype affects the pharmacokinetics of dimemorfan in healthy Chinese subjects.
P2860
Q24621760-4953962B-5915-45FD-9AEB-9DDE3420B019Q28468449-CEDB526D-B18E-4BB8-A34C-6B0E70D4C1F7Q28546094-F25A0907-26B3-4B32-A221-25B8D219F722Q33589336-0F528607-C889-475B-A4E8-947D428994D3Q33651583-4AAF7712-67E1-4419-AC89-98204B6DE8FEQ33756964-6D80DFC0-717B-4A23-85D9-BC985E7767A9Q33935217-E506CD92-8D66-46EB-B6B3-607D63792EE1Q34501025-FD01C5D8-D1FF-4A39-AB84-5BBFA14F5B72Q35020403-15AFE441-3FE8-4032-BAFD-FEA7D710D881Q35793103-2E241A62-1AFB-417C-981C-EE77D0F04AAAQ35884159-9770E566-6A9F-4446-A7C0-8068F142E2BEQ36441557-BB191340-E6F4-476F-8F87-1D6DFE7E1F30Q36550926-9E9A3785-7E5A-4DD7-95E8-81FD94652A45Q36808170-93223AC2-7A80-482D-A472-1B982F50AFEAQ36909858-C3B518D4-16F8-43FB-B99B-505296975719Q36924724-031E96F7-CAD1-4D31-9807-DD51F11C5723Q36925964-A66631D5-D13B-436C-B59D-7B6F4B2F1C28Q36962516-649AED7E-F8F5-494A-9477-7FAC17F2F975Q37059764-C894E253-951E-4445-91E4-54512CB06FDAQ37140638-8074085A-4A8D-48DC-BA72-1C1FAF6A39CFQ37170578-004AC13C-C104-450E-9624-B0810387E4A3Q38099372-5FE8C561-D252-48EF-B3D9-6D929EC004DFQ38103593-6B6F271C-C248-4B91-A596-0D1C1D9AB387Q38105253-77FDFD19-4323-42F7-A8BD-E6F01430B90AQ38188600-AD7FBFF2-EA45-4CAD-93CF-5722AFA14D64Q38629670-78045D2A-5DFD-4BF8-AD0E-E08B330980A8Q38842969-EBF01FF0-2297-4B65-B4BC-C19A8AAC4E88Q39042324-F051C6CD-42BC-49FA-99B3-829CCAC7C0F4Q39752018-40A24578-6E81-42BD-8EC3-14806FA7C902Q40789462-D89455CC-97E6-469F-898D-F2D40F6B9D42Q40946755-4E9478A5-ACE2-4253-8BE2-5AB89059B660Q41684510-9A793D19-EF3C-42BE-8E4B-12945206B6F1Q43477148-2E45ABDD-85B9-4692-8AFD-27D9B02A0A36Q43784186-54F601C9-14FD-485A-B4C0-84E6533C3EDAQ45851914-F515BEFE-D468-4F08-8631-590A7EAC220AQ47155427-67F5D51A-2141-4543-9D6D-AA15604A60E6Q48125765-CC1B566B-B264-44B5-B285-0ED4F691BC82Q50049636-C32BF337-9C88-4758-82B0-71155004B9C0Q53833189-72719E3B-4AB2-466D-A785-4DD0F3905264Q54193657-A7F1E3F5-F2F4-4F3A-ABB3-EA92212F7349
P2860
Impact of CYP2D6, CYP3A5, CYP2C9 and CYP2C19 polymorphisms on tamoxifen pharmacokinetics in Asian breast cancer patients
description
2011 nî lūn-bûn
@nan
2011 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Impact of CYP2D6, CYP3A5, CYP2 ...... n Asian breast cancer patients
@ast
Impact of CYP2D6, CYP3A5, CYP2 ...... n Asian breast cancer patients
@en
Impact of CYP2D6, CYP3A5, CYP2 ...... n Asian breast cancer patients
@nl
type
label
Impact of CYP2D6, CYP3A5, CYP2 ...... n Asian breast cancer patients
@ast
Impact of CYP2D6, CYP3A5, CYP2 ...... n Asian breast cancer patients
@en
Impact of CYP2D6, CYP3A5, CYP2 ...... n Asian breast cancer patients
@nl
prefLabel
Impact of CYP2D6, CYP3A5, CYP2 ...... n Asian breast cancer patients
@ast
Impact of CYP2D6, CYP3A5, CYP2 ...... n Asian breast cancer patients
@en
Impact of CYP2D6, CYP3A5, CYP2 ...... n Asian breast cancer patients
@nl
P2093
P2860
P1476
Impact of CYP2D6, CYP3A5, CYP2 ...... n Asian breast cancer patients
@en
P2093
Balram Chowbay
Edmund J D Lee
Joanne S L Lim
Mabel Wong
Nan S Wong
Onkar Singh
Raymond C H Ng
Xiang A Chen
P2860
P304
P356
10.1111/J.1365-2125.2011.03905.X
P407
P50
P577
2011-05-01T00:00:00Z